Fig. 6: CCS improved the hepatic steatosis, intestinal barrier, and altered gut microbiota in HFD fed rats. | npj Science of Food

Fig. 6: CCS improved the hepatic steatosis, intestinal barrier, and altered gut microbiota in HFD fed rats.

From: Stigmasterol attenuates hepatic steatosis in rats by strengthening the intestinal barrier and improving bile acid metabolism

Fig. 6

a Changes in the body weight of rats over 11 weeks; b organ weights of rats in the end of the experiment; c serum levels of lipid (TC, TG, and LDL-C); d histopathological staining of liver, ileum, and colon (H&E, ORO, and AB-PAS), Scale bar as above; e immunohistochemistry of Occludin and ZO-1 protein in ileum, Scale bar: 200 μm; f the ratio of HDL-C/TC in serum; g the α-diversity index (chao1) of gut microbiota; h relative abundance of gut microbiota in the phylum and family level; i the β-diversity analysis (PCoA) of gut microbiota; (j) relative abundance of biomarker genra in the family and genus level. Data are expressed as mean±standard deviation. One-way ANOVA was used to analyze statistical differences; compared with control group, #P < 0.05, ##P < 0.01; compared with HFD group, *P < 0.05, **P < 0.01.

Back to article page